NCT06478264 - A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 13, 2024

Primary Completion Date

July 13, 2026

Study Completion Date

July 13, 2027

Conditions

Esophageal Small Cell Carcinoma

Interventions

DRUG

Etoposide

100mg/m\^2, intravenous infusion for 1-3 days,21 days/cycle, 4 cycles

DRUG

Cisplatin

25mg/m\^2 ,intravenous infusion for 1-3 days ,21 days/cycle, 4 cycles

DRUG

Carboplatin

Carboplatin (AUC = 5) on 1 Day,21 days/cycle, 4 cycles ;

DRUG

Adebrelimab

1200mg adebrelimab was given intravenously on 2 day after chemotherapy,21 days/cycle, continuous use.

RADIATION

radiotherapy

Stage I-IVa , prescription dose: PTV 50Gy/25f. Stage IVb ,prescribed dose: PTV 30Gy/10f.

All Listed Sponsors

lead

Zhangzhou Municipal Hospital

OTHER